Showing 841-850 of 1161 results for "".
- FDA Clears New World Medical's VIA360 Surgical Systemhttps://modernod.com/news/fda-clears-new-world-medicals-via360-surgical-system/2482667/New World Medical has received 510(k) clearance from the FDA for its VIA360 Surgical System for the delivery of controlled amounts of viscoelastic fluid during ophthalmic surgeries. The VIA360, which is also indicated to cut trabecular meshwork tissue during trabecul
- AI Optics Receives FDA Clearance for Handheld Retinal Imaging Systemhttps://modernod.com/news/ai-optics-receives-fda-clearance-for-handheld-retinal-imaging-system/2482650/AI Optics has received FDA 510(k) clearance for its Sentinel Camera, a handheld retinal imaging system designed to capture high-quality images of the eye. Al Optics said the device helps to address critical gaps in retinal disease screening through a
- CorNeat EverPatch Synthetic Tissue Substitute Now Available in the UShttps://modernod.com/news/corneat-everpatch-synthetic-tissue-substitute-now-available-in-the-us/2482138/CorNeat Vision announced the commerical launch of the CorNeat EverPatch, a synthetic tissue-integrating matrix for ocular surface surgeries. The EverPatch, which received FDA 510(k) clearance in June 2023, offers a combination of features that provide an advantage over ex
- Belkin Vision Announces FDA Clearance for the Eagle for Selective Laser Trabeculoplastyhttps://modernod.com/news/belkin-vision-announces-fda-clearance-for-the-eagle-device/2482005/Belkin Vision has received FDA 510(k) clearance for the Eagle device, a Q-switched, 532 nm-wavelength, frequency-doubled Nd:YAG laser intended for use in performing selective laser trabeculoplasty (SLT). Belkin describes the Eagle as the first and only contactless l
- Ocuphire Pharma Names Joseph Schachle as COOhttps://modernod.com/news/ocuphire-pharma-names-joseph-schachle-as-coo/2481981/Ocuphire Pharma announced the appointment of Joseph (Joe) K. Schachle, MBA, into the newly created role of Chief Operating Officer, effective immediately. Ocuphire is a clinical-stage company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refra
- Lensar and Oertli Provide Update on Plans to Integrate Phaco Technology into the ALLY Adaptive Cataract Treatment Systemhttps://modernod.com/news/lensar-and-oertli-provide-update-on-plans-to-integrate-phaco-technology-into-the-ally-adaptive-cataract-treatment-system/2481923/Lensar said it is closer to its plans to integrate phacoemulsification technology from Oertli Instrumente into the ALLY Adaptive Cataract Treatment System. Oertli filed with the FDA a 510(k) for their Faros device, which if cleared, will bring Lensar a step closer to deliver comb
- Altris Receives FDA Clearance of Altris IMS Platform for OCT Scan Analysishttps://modernod.com/news/altris-receives-fda-clearance-of-altris-ims-platform-for-oct-scan-analysis/2481833/Altris received FDA 510(k) clearance for the Altris IMS, the company’s image, and data management platform. The Altris platform is designed to store, organize, and support in-depth analysis of Optical Coherence Tomography (OCT) scans. The platform provides secu
- Euclid Vision Issues Statement on the Passing of Co-Founder George Gladyhttps://modernod.com/news/euclid-vision-issues-statement-on-the-passing-of-co-founder-george-glady/2481771/Euclid Vision issued a statement memorializing George Glady, one of the company's founders who has passed away. Mr. Glady was a pioneer in Ortho-K, which has been an innovation used by millions of patients around the world to slow the progression of myopia. The state
- Harrow Acquires Santen’s Branded Ophthalmic Portfoliohttps://modernod.com/news/harrow-acquires-santens-branded-ophthalmic-portfolio/2481735/Harrow announced it is acquiring certain US and Canadian commercial rights to several branded ophthalmic products from Santen. According to an 8-K filing with the SEC, Harrow will make a one-time upfront payment of $8 million, with future near- and medium-term milestone
- FDA Clears CorNeat EverPatch, World's First Non-Degradable, Synthetic Tissue Substitute for Ophthalmic Surgeryhttps://modernod.com/news/fda-clears-corneat-everpatch-worlds-first-non-degradable-synthetic-tissue-substitute-for-ophthalmic-surgery/2481668/The FDA has granted 510(k) clearance to CorNeat Vision's EverPatch, which the company describes as the first synthetic, non-degradable tissue-integrating matrix for use in ophthalmic surgeries. It is composed of a non-woven, polymer matrix which integrates with surrounding tissue an